Investigation of chlamydia trachomatis seropositivity in patients with cervical cancer;Servikal kanserli hastalarda chlamydia trachomatis seropozitifliǧ inin araştinlmasi

Mikrobiyoloji Bulteni

Volumn 47, Issue 4, 2013, Pages 702-707

  Önel, Mustafa ^a   Küçücük, Seden ^b   Töre, Cökhan ^b   Aǧaçfidan, Ali ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cervical cancer; Chlamydia trachomatis; Microimmunofluorescence (MIF); Seropositivity

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLASSIFICATION; FEMALE; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; UTERINE CERVIX TUMOR;

ADULT; ANTIBODIES, BACTERIAL; CASE-CONTROL STUDIES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS;

EID: 84890368508     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: 10.5578/mb.5559     Document Type: Article

References (22)

1. Mylonas I. Female genital Chlamydia trachomatis infection: where are we heading? Arch Gynecol Obstet 2012; 285(5): 1271-85.
2. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. http://whqlibdoc.who.int/hq/2001/WHO-HIV-AIDS-2001.02.pdf
3. Roset Bahmanyar E., Paavonen J, Naud P., et al.; HPV PATRICIA Study Group. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol 2012; 127(3): 440-50.
4. Konopnicki D, Manigart Y, Gilles C., et al High-risk human papillomavirus infection in HIV-positive African women living in Europe. J Int AIDS Soc 2013; 16: 18023.
5. Trottier H, Franco EL The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24 (SUPPL. 1):S1-15.
6. Finan RR, Tamim H, Almawi WY Identification of Chlamydia trachomatis DNA in human papillomavirus (HPV) positive women with normal and abnormal cytology. Arch Gynecol Obstet 2002; 266(3): 168-71.
7. Tamim H, Finan RR, Sharida H.E., Rashid M., Almawi WY Cervicovaginal coinfections with human papillomavirus and Chlamydia trachomatis. Diagn Microbiol Infect Dis 2002; 43(4): 277-81.
8. Simonetti AC, Melo JH, de Souza PR, Bruneska D, de Lima Filho JL. Immunological's host profile for HPV and Chlamydia trachomatis, a cervical cancer cofactor. Microbes Infect 2009; 11 (4): 435-42.
9. Deluca GD, Basiletti J, Schelover E., et al Chlamydia trachomatis as a probable cofactor in human papillomavirus infection in aboriginal women from northeastern Argentina. Braz J Infect Dis 2011; 15(6): 567-72.
10. da Silva Barros NK, Costa MC, Alves R.R., et al. Association of HPV infection and Chlamydia trachomatis seropositive in cases of cervical neoplasia in Midwest Brazil. J Med Virol 2012; 84(7): 1143-50.
11. de Abreu A.L., Nogara PR, Souza R.P., et al Molecular detection of HPV and Chlamydia trachomatis infections in Brazilian women with abnormal cervical cytology. Am J Trop Med Hyg 2012; 87(6): 1149-51.
12. Farivar TN, Johari P. Lack of association between Chlamydia trachomatis infection and cervical cancer-Taq Man realtime PCR assay findings. Asian Pac J Cancer Prev 2012; 13(8): 3701-4.
13. Bhatla N, Puri K, Joseph E., Kriplani A, Iyer VK, Sreenivas V. Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia - a pilot study. Indian J Med Res 2013; 137(3): 533-9.
14. Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007; 23(4): 213-27.
15. Brankovic I, Verdonk P, Klinge I. Applying a gender lens on human papillomavirus infection: cervical cancer screening, HPV DNA testing, and HPV vaccination. Int J Equity Health 2013; 12:14.
16. Vaccarella S, Lortet-Tieulent J, Plummer M., Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013; pii: S0959-8049(13)00358-4.
17. Gopalkrishna V, Aggarwal N, Malhotra V.L., et al Chlamydia trachomatis and human papillomavirus infection in Indian women with sexually transmitted diseases and cervical precancerous and cancerous lesions. Clin Microbiol Infect 2000; 6(2): 88-93.
18. Paavonen J. Chlamydia trachomatis infections of the female genital tract: state of the art. Ann Med 2012; 44(1): 18-28.
19. Lehtinen M, Ault KA, Lyytikainen E, et al Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect 2011; 87(5): 372-6.
20. Arnheim Dahlström L, Andersson K, Luostarinen T, et al. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol Biomarkers Prev 2011; 20(12): 2541-50.
21. Anttila T, Saikku P, Koskela P., et al Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285(1): 47-51.
22. Smith JS, Muñoz N, Herrero R., et al Evidence for Chlamydia trachomatis as a human papillomavirus cofac-tor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002; 185(3): 324-31.